27 hasil untuk "Jen-Ruei Chen"
Menampilkan 21–27 · 0,73 detik · RSS
-
Artikel Jurnal
Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer
Abstract Background Sarcopenia is commonly observed in patients with advanced‐stage epithelial ovarian cancer (EOC). However, the effect of body composition changes—during primary debulking surgery (PDS) and adjuvant platinum‐based chemotherapy—on outcomes of patients with advanced‐stage EOC is…
-
Artikel Jurnal
Is conization once following by simple hysterectomy sufficient for all clinical stage IA1 cervical squamous cell carcinoma?
Objective: The goal of this study is to assess the feasibility of simple extrafascial hysterectomy for patients with clinical stage IA1 cervical squamous cell carcinoma (SCC) after once conization regardless of any pathologic risk factor. Materials and Methods: All cases with T1a1, SCC lesion in…
-
Artikel Jurnal
Villoglandular Adenocarcinoma of the Uterine Cervix: An Analysis of 12 Clinical Cases
Background: Villoglandular adenocarcinoma (VGA) of the uterine cervix is a relatively rare subtype of endocervical adenocarcinomas that often occurs in early reproductive women. Methods: Clinical cases were retrospectively collected from the cancer registry systems at Mackay Memorial Hospital…
-
Artikel Jurnal
Outcome of ovarian preservation during surgical treatment for endometrial cancer: A Taiwanese Gynecologic Oncology Group study
Objective: The goal of this study was to investigate the impact of ovarian preservation on the survival of women with early-stage endometrial cancer, particularly young women. Materials and methods: A study cohort of 64 patients with histologically confirmed early-stage endometrial cancer was…
-
Artikel Jurnal
Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review
Endometrial stromal tumors are rare uterine tumors (
-
Artikel Jurnal
Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review
Uterine sarcomas account for 3–7% of all uterine cancers. Because of their rarity, unknown etiology, and highly divergent genetic aberration, there is a lack of consensus on risk factors for occurrence and predictive poor outcomes as well as optimal therapeutic choices. Tumor types according to the…
-
Artikel Jurnal
Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review
Uterine sarcoma is a very aggressive and highly lethal disease. Even after a comprehensive staging surgery or en block cytoreduction surgery followed by multimodality therapy (often chemotherapy and/or radiation therapy), many patients relapse or present with distant metastases, and finally die of…